Dermata Therapeutics pivots to OTC; plans acne kit launch mid-2026, reports Q3 cash $4.7M

Dermata Therapeutics, Inc.

Cash and cash equivalents of $4.7M as of Sep 30, 2025; expected to fund operations into Q2 2026.
R&D expenses dropped to $0.5M in Q3 2025 from $2.4M in Q3 2024 as XYNGARI Phase 3 trial concluded.
Strategic pivot to OTC dermatology; first product is a once-weekly acne kit using Spongilla technology, launch mid-2026.
Company plans to sell OTC acne kit directly to consumers, estheticians, and dermatologists for in-office use.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.